The challenge

A global medical technology company asked us to assess the cost-effectiveness of their medical device for treating a neurological condition. They wanted to compare the combined use of their device and medicines with the sole use of medicines. The client needed a cost-effectiveness model that could inform future health technology assessments, that was sufficiently flexible to allow internal stakeholders to identify key drivers of cost-effectiveness, and that could evolve to take into account new research findings and additional comparators.  

The approach

After we thoroughly reviewed the clinical and economic literature, we realised that we would need to be innovative in developing our model in order to robustly synthesise a heterogeneous evidence base. We made use of individual-patient data (IPD), utility mapping and real world evidence (RWE) to inform the model, including bespoke statistical analysis of registry data. Through continuous discussion with the client as well as trusted clinical and economic experts, we developed a user-friendly, highly adjustable cost-effectiveness model that could function robustly for different scenarios and local settings.

The outcome

After ensuring that the model met the client’s expectations, we helped roll it out to regional stakeholders and lead training sessions to explain its use and suggest how best to apply it to the available evidence. We also performed a stand-alone cost-effectiveness analysis that was accepted for publication in a well-regarded academic journal, given that our work used contemporary estimates of costs, replacement, and discontinuation to estimate the cost-effectiveness of the device in the English NHS setting.

We continue to work closely with the client to support their submission strategies in multiple countries, and we advise them on critical areas for further research and development. We also work with the client and regional stakeholders to adapt the model appropriately as more evidence becomes available.